Lantern Pharma Advocates for AI-Driven Transformation of Biotech Industry at BioNTX Summit

Lantern Pharma, a Dallas-based clinical-stage biopharmaceutical company, has aligned with industry leaders calling for fundamental changes to what they describe as a broken biotech model. The company's stance was highlighted during the 2025 BioNTX iC3 Summit, where CEO Panna Sharma served as both moderator and panelist. Sharma emphasized that despite available technology, drug development remains largely manual, stating that the industry hasn't adopted technological solutions quickly enough to address systemic inefficiencies.

The summit, covered in a Dallas Innovates article, featured biotech executives who collectively declared the traditional drug development model unsustainable. Sharma specifically pointed to Lantern Pharma's RADR AI platform as a solution that can streamline discovery processes, accelerate clinical timelines, and significantly reduce costs. The RADR platform leverages over 200 billion oncology-focused data points and utilizes more than 200 machine learning algorithms to address what the company describes as billion-dollar problems in oncology drug development.

Lantern Pharma's approach represents a shift toward data-driven drug development that could create a more sustainable future for the biotech industry. The company currently maintains a pipeline of therapies spanning multiple cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. Their development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials, with the combined annual market potential of their pipeline estimated at over $15 billion.

The company's news and updates are available in their online newsroom, providing investors and stakeholders with ongoing information about their AI-driven approach to oncology treatment development. This positioning comes at a critical time when the pharmaceutical industry faces increasing pressure to reduce development costs and accelerate the delivery of new treatments to patients.

The broader implications of this industry movement extend beyond Lantern Pharma's specific technology. As biotech companies grapple with rising research and development expenses, AI-driven platforms offer the potential to make drug discovery more efficient and targeted. The summit discussion reflects growing consensus that technological innovation must play a central role in reshaping how new therapies are developed and brought to market, particularly in complex fields like oncology where treatment development traditionally involves extensive time and resource investments.

For Texas's growing biotech sector, Lantern Pharma's leadership in advocating for AI adoption positions the state as an innovation hub in pharmaceutical technology. The company's Dallas headquarters places it at the center of a rapidly expanding life sciences ecosystem that could benefit from more efficient drug development models. The potential cost savings and accelerated timelines offered by AI platforms like RADR could make Texas more attractive for biotech investment and talent acquisition.

The economic impact of transforming drug development extends beyond the pharmaceutical industry itself. More efficient cancer treatment development could lead to earlier patient access to innovative therapies, potentially reducing healthcare costs and improving outcomes. For investors and stakeholders, the shift toward AI-driven approaches represents both a technological revolution and a fundamental change in how biotech companies create value and manage risk in their development pipelines.